{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T12:17:06Z","timestamp":1774527426574,"version":"3.50.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,1,4]],"date-time":"2022-01-04T00:00:00Z","timestamp":1641254400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,4]],"date-time":"2022-01-04T00:00:00Z","timestamp":1641254400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Patients with Inflammatory Bowel Disease (IBD) are at increased risk of serious infections, including vaccine preventable diseases. Current evidence suggests uptake of additional recommended special risk vaccinations is low. Identification of IBD patients prior to commencing immunosuppressive therapy allows for optimisation of vaccination, including timely administration of live-attenuated and additional recommended vaccines, such as influenza and pneumococcal vaccines.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Paediatric patients (0\u201318 years) seen at the tertiary Royal Children\u2019s Hospital, Melbourne, Australia, with a recent diagnosis of IBD were referred by the Gastroenterology Unit to our Specialist Immunisation Clinic (SIC) for assessment and provision of routine and special risk vaccines. Data was collected via a standardised REDCap questionnaire completed in or post attendance at the SIC and included serology results where available.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Sixty-nine paediatric patients were recruited to the study between 2014 and 2017. Median age at IBD diagnosis was 11.25 years (IQR 4.64 years), with median time between diagnosis and SIC review of 0.88 years (IQR 2.84 years). At initial review 84.1% (58\/69) of patients were up to date with vaccines on the Australian National Immunisation Program (NIP) schedule. Of those who were tested, serological evidence of immunity was demonstrated in 38.3% (23\/60) of patients for Hepatitis B, 66.7% (36\/54) for measles, 51.9% (28\/54) for rubella and 41.9% (26\/62) for Varicella Zoster Virus. Prior to SIC review 47.8% (33\/69) had additional vaccinations and 92.8% (64\/69) had vaccinations administered in the 12 months following SIC assessment. The Pneumococcal conjugate vaccine (76.8%, 53\/69) was the most commonly administered vaccine after SIC review, followed by influenza vaccine (69.6%, 48\/69). Within 12 months of SIC review 43.5% (30\/69) of patients had completed the schedule and were up-to-date as recommended by the SIC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Children with IBD and other special risk groups can benefit from early referral to a SIC team to ensure optimal administration of routine and additionally recommended vaccines, especially live and additional special risk vaccines. The value of optimising immunisations could also be applied to other special risk groups, including adult IBD cohorts, particularly those commencing newer biologic immunosuppressive medications.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12879-021-06976-x","type":"journal-article","created":{"date-parts":[[2022,1,4]],"date-time":"2022-01-04T05:08:03Z","timestamp":1641272883000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Immunisation status of children and adolescents with a new diagnosis of inflammatory bowel disease"],"prefix":"10.1186","volume":"22","author":[{"given":"Timothy","family":"Ford","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margie","family":"Danchin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alissa","family":"McMinn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kirsten","family":"Perrett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George","family":"Alex","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nigel W.","family":"Crawford","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,1,4]]},"reference":[{"issue":"1","key":"6976_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/ibd.22997","volume":"19","author":"V Schildkraut","year":"2013","unstructured":"Schildkraut V, Alex G, Cameron DJS, et al. Sixty-year study of incidence of childhood ulcerative colitis finds eleven-fold increase beginning in 1990s. Inflamm Bowel Dis. 2013;19(1):1\u20136. https:\/\/doi.org\/10.1002\/ibd.22997.","journal-title":"Inflamm Bowel Dis"},{"issue":"3","key":"6976_CR2","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1046\/j.1440-1746.2003.02975.x","volume":"18","author":"N Phavichitr","year":"2003","unstructured":"Phavichitr N, Cameron DJS, Catto-Smith AG. Increasing incidence of Crohn\u2019s disease in Victorian children. J Gastroenterol Hepatol. 2003;18(3):329\u201332. https:\/\/doi.org\/10.1046\/j.1440-1746.2003.02975.x.","journal-title":"J Gastroenterol Hepatol"},{"issue":"8","key":"6976_CR3","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1111\/j.1572-0241.2006.00646.x","volume":"101","author":"GY Melmed","year":"2006","unstructured":"Melmed GY, Ippoliti AF, Papadakis KA. Patients with inflammatory bowel disease are at risk for vaccine-preventable illnesses. Am J Gastroenterol. 2006;101(8):1834\u201340. https:\/\/doi.org\/10.1111\/j.1572-0241.2006.00646.x.","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"6976_CR4","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1586\/erv.10.157","volume":"10","author":"NW Crawford","year":"2011","unstructured":"Crawford NW, Bines JE, Royle J, Buttery JP. Optimizing immunization in pediatric special risk groups. Expert Rev Vaccines. 2011;10(2):175\u201386. https:\/\/doi.org\/10.1586\/erv.10.157.","journal-title":"Expert Rev Vaccines"},{"issue":"9","key":"6976_CR5","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1093\/cid\/cit489","volume":"57","author":"SS Toussi","year":"2013","unstructured":"Toussi SS, Pan N, Walters HM, Walsh TJ. Infections in children and adolescents with juvenile idiopathic arthritis and inflammatory bowel disease treated with tumor necrosis factor-\u03b1 inhibitors: systematic review of the literature. Clin Infect Dis. 2013;57(9):1318\u2013130. https:\/\/doi.org\/10.1093\/cid\/cit489.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"6976_CR6","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1053\/j.gastro.2008.01.012","volume":"134","author":"M Toruner","year":"2008","unstructured":"Toruner M, Loftus EV, Harmsen WS, et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology. 2008;134(4):929\u201336. https:\/\/doi.org\/10.1053\/j.gastro.2008.01.012.","journal-title":"Gastroenterology"},{"issue":"12","key":"6976_CR7","first-page":"2517","volume":"31","author":"H Vonkeman","year":"2004","unstructured":"Vonkeman H, ten Napel C, Rasker H, van de Laar M. Disseminated primary varicella infection during infliximab treatment. J Rheumatol. 2004;31(12):2517\u20138.","journal-title":"J Rheumatol"},{"issue":"9","key":"6976_CR8","first-page":"1534","volume":"92","author":"IA Mouzas","year":"1997","unstructured":"Mouzas IA, Greenstein AJ, Giannadaki E, Balasubramanian S, Manousos ON, Sachar DB. Management of varicella infection during the course of inflammatory bowel disease. Am J Gastroenterol. 1997;92(9):1534\u20137.","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"6976_CR9","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/j.1365-2036.2009.04161.x","volume":"31","author":"JF Rahier","year":"2010","unstructured":"Rahier JF, Yazdanpanah Y, Viget N, Travis S, Colombel JF. Review article: influenza A (H1N1) virus in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2010;31(1):5\u201310. https:\/\/doi.org\/10.1111\/j.1365-2036.2009.04161.x.","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"6976_CR10","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1097\/00054725-200111000-00009","volume":"7","author":"MA Ritz","year":"2001","unstructured":"Ritz MA, Jost R. Severe pneumococcal pneumonia following treatment with infliximab for Crohn\u2019s disease. Inflamm Bowel Dis. 2001;7(4):327. https:\/\/doi.org\/10.1097\/00054725-200111000-00009.","journal-title":"Inflamm Bowel Dis"},{"issue":"38","key":"6976_CR11","doi-asserted-by":"publisher","first-page":"6167","DOI":"10.3748\/wjg.v12.i38.6167","volume":"12","author":"J Bhatia","year":"2006","unstructured":"Bhatia J, Bratcher J, Korelitz B, et al. Abnormalities of uterine cervix in women with inflammatory bowel disease. World J Gastroenterol. 2006;12(38):6167\u201371.","journal-title":"World J Gastroenterol"},{"issue":"3","key":"6976_CR12","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1111\/j.1572-0241.2007.01582.x","volume":"103","author":"S Kane","year":"2008","unstructured":"Kane S, Khatibi B, Reddy D. Higher incidence of abnormal Pap smears in women with inflammatory bowel disease. Am J Gastroenterol. 2008;103(3):631\u20136. https:\/\/doi.org\/10.1111\/j.1572-0241.2007.01582.x.","journal-title":"Am J Gastroenterol"},{"key":"6976_CR13","unstructured":"Australian Government. Australian immunisation handbook. Department of Health website. https:\/\/immunisationhandbook.health.gov.au\/. Updated June 8,\u00a02018. Accessed 28\u00a0Feb\u00a02019."},{"key":"6976_CR14","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/1471-230X-11-87","volume":"11","author":"NW Crawford","year":"2011","unstructured":"Crawford NW, Catto-Smith AG, Oliver MR, Cameron DJ, Buttery JP. An Australian audit of vaccination status in children and adolescents with inflammatory bowel disease. BMC Gastroenterol. 2011;11:87. https:\/\/doi.org\/10.1186\/1471-230X-11-87.","journal-title":"BMC Gastroenterol"},{"issue":"4","key":"6976_CR15","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1111\/irv.12236","volume":"8","author":"A Banaszkiewicz","year":"2014","unstructured":"Banaszkiewicz A, Klincewicz B, Lazowska-Przeorek I, et al. Influenza vaccination coverage in children with inflammatory bowel disease. Influenza Other Respir Viruses. 2014;8(4):431\u20135. https:\/\/doi.org\/10.1111\/irv.12236.","journal-title":"Influenza Other Respir Viruses"},{"issue":"1","key":"6976_CR16","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1038\/ajg.2009.523","volume":"105","author":"GY Melmed","year":"2010","unstructured":"Melmed GY, Agarwal N, Frenck RW, et al. Immunosuppression impairs response to pneumococcal polysaccharide vaccination in patients with inflammatory bowel disease. Am J Gastroenterol. 2010;105(1):148\u201354. https:\/\/doi.org\/10.1038\/ajg.2009.523.","journal-title":"Am J Gastroenterol"},{"issue":"41","key":"6976_CR17","doi-asserted-by":"publisher","first-page":"5464","DOI":"10.1016\/j.vaccine.2015.08.011","volume":"33","author":"B Kants\u00f8","year":"2015","unstructured":"Kants\u00f8 B, Halkj\u00e6r SI, Thomsen O\u00d8, Belard E, Gottschalck IB, J\u00f8rgensen CS, et al. Immunosuppressive drugs impairs antibody response of the polysaccharide and conjugated pneumococcal vaccines in patients with Crohn\u2019s disease. Vaccine. 2015;33(41):5464\u20139. https:\/\/doi.org\/10.1016\/j.vaccine.2015.08.011.","journal-title":"Vaccine"},{"key":"6976_CR18","unstructured":"Australian Government. Australian Statistical geography standard (ASGS): volume\u00a05\u2014Remoteness structure, July 2016. Australian Bureau of Statistics website. http:\/\/www.abs.gov.au\/AUSSTATS\/abs@.nsf\/DetailsPage\/1270.0.55.005July%202016?OpenDocument. Updated March 16,\u00a02018. Accessed 17\u00a0Mar\u00a02018."},{"key":"6976_CR19","unstructured":"Victoria State Government. Vaccine history timeline. Department of Health and Human Services website. https:\/\/www2.health.vic.gov.au\/public-health\/immunisation\/immunisation-schedule-vaccine-eligibility-criteria\/vaccine-history-timeline. Updated 2018. Accessed 17\u00a0Mar\u00a02018."},{"key":"6976_CR20","unstructured":"Australian Government. Immunisation coverage rates for all children. Department of Health website. https:\/\/beta.health.gov.au\/topics\/immunisation\/childhood-immunisation-coverage\/immunisation-coverage-rates-for-all-children. Updated February, 5 2018. Accessed 16\u00a0Mar\u00a02018."},{"issue":"1","key":"6976_CR21","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1097\/MPG.0000000000000730","volume":"61","author":"R Lester","year":"2015","unstructured":"Lester R, Lu Y, Tung J. Survey of immunization practices in patients with inflammatory bowel disease among pediatric gastroenterologists. J Pediatr Gastroenterol Nutr. 2015;61(1):47\u201351. https:\/\/doi.org\/10.1097\/MPG.0000000000000730.","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"1100","key":"6976_CR22","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1136\/postgradmedj-2016-134266","volume":"93","author":"GE Gurvits","year":"2017","unstructured":"Gurvits GE, Lan G, Tan A, Weissman A. Vaccination practices in patients with inflammatory bowel disease among general internal medicine physicians in the USA. Postgrad Med J. 2017;93(1100):333\u20137. https:\/\/doi.org\/10.1136\/postgradmedj-2016-134266.","journal-title":"Postgrad Med J"},{"issue":"20","key":"6976_CR23","doi-asserted-by":"publisher","first-page":"2633","DOI":"10.1016\/j.vaccine.2017.03.080","volume":"35","author":"HY Jiang","year":"2017","unstructured":"Jiang HY, Wang SY, Deng M, Li YC, Ling ZX, Shao L, et al. Immune response to hepatitis B vaccination among people with inflammatory bowel diseases: a systematic review and meta-analysis. Vaccine. 2017;35(20):2633\u201341. https:\/\/doi.org\/10.1016\/j.vaccine.2017.03.080.","journal-title":"Vaccine"},{"issue":"40","key":"6976_CR24","doi-asserted-by":"publisher","first-page":"11273","DOI":"10.3748\/wjg.v21.i40.11273","volume":"21","author":"AC Mar\u00edn","year":"2015","unstructured":"Mar\u00edn AC, Gisbert JP, Chaparro M. Immunogenicity and mechanisms impairing the response to vaccines in inflammatory bowel disease. World J Gastroenterol. 2015;21(40):11273\u201381. https:\/\/doi.org\/10.3748\/wjg.v21.i40.11273.","journal-title":"World J Gastroenterol"},{"issue":"8","key":"6976_CR25","doi-asserted-by":"publisher","first-page":"2446","DOI":"10.1007\/s10620-015-3631-y","volume":"60","author":"DL Nguyen","year":"2015","unstructured":"Nguyen DL, Nguyen ET, Bechtold ML. Effect of immunosuppressive therapies for the treatment of inflammatory bowel disease on response to routine vaccinations: a meta-analysis. Dig Dis Sci. 2015;60(8):2446\u201353. https:\/\/doi.org\/10.1007\/s10620-015-3631-y.","journal-title":"Dig Dis Sci"},{"issue":"3","key":"6976_CR26","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1097\/MIB.0000000000000615","volume":"22","author":"J deBruyn","year":"2016","unstructured":"deBruyn J, Fonseca K, Ghosh S, Panaccione R, Gasia MF, Ueno A, et al. Immunogenicity of influenza vaccine for patients with inflammatory bowel disease on maintenance infliximab therapy: a randomized trial. Inflamm Bowel Dis. 2016;22(3):638\u201347. https:\/\/doi.org\/10.1097\/MIB.0000000000000615.","journal-title":"Inflamm Bowel Dis"},{"issue":"8","key":"6976_CR27","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1097\/MIB.0000000000000448","volume":"21","author":"S Dezfoli","year":"2015","unstructured":"Dezfoli S, Horton HA, Thepyasuwan N, Berel D, Targan SR, Vasiliauskas EA, et al. Combined immunosuppression impairs immunogenicity to tetanus and pertussis vaccination among patients with inflammatory bowel disease. Inflamm Bowel Dis. 2015;21(8):1754\u201360. https:\/\/doi.org\/10.1097\/MIB.0000000000000448.","journal-title":"Inflamm Bowel Dis"},{"issue":"12","key":"6976_CR28","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1111\/j.1365-2036.2012.05110.x","volume":"35","author":"JP Gisbert","year":"2012","unstructured":"Gisbert JP, Menchen L, Garcia-Sanchez V, Marin I, Villagrasa JR, Chaparro M. Comparison of the effectiveness of two protocols for vaccination (standard and double dosage) against hepatitis B virus in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2012;35(12):1379\u201385. https:\/\/doi.org\/10.1111\/j.1365-2036.2012.05110.x.","journal-title":"Aliment Pharmacol Ther"},{"issue":"8","key":"6976_CR29","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1007\/s00535-015-1042-7","volume":"50","author":"H Matsumoto","year":"2015","unstructured":"Matsumoto H, Ohfuji S, Watanabe K, Yamagami H, Fukushima W, Maeda K, et al. Booster influenza vaccination does not improve immune response in adult inflammatory bowel disease patients treated with immunosuppressives: a randomized controlled trial. J Gastroenterol. 2015;50(8):876\u201386. https:\/\/doi.org\/10.1007\/s00535-015-1042-7.","journal-title":"J Gastroenterol"},{"issue":"9","key":"6976_CR30","first-page":"1153","volume":"168","author":"R Long","year":"2003","unstructured":"Long R, Gardam M. Tumour necrosis factor-\u03b1 inhibitors and the reactivation of latent tuberculosis infection. Can Med Assoc J. 2003;168(9):1153\u20136.","journal-title":"Can Med Assoc J"},{"issue":"5","key":"6976_CR31","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s00431-013-2207-0","volume":"173","author":"R Longuet","year":"2014","unstructured":"Longuet R, Willot S, Gini\u00e8s JL, P\u00e9latan C, Breton E, Segura JF, et al. Immunization status in children with inflammatory bowel disease. Eur J Pediatr. 2014;173(5):603\u20138. https:\/\/doi.org\/10.1007\/s00431-013-2207-0.","journal-title":"Eur J Pediatr"},{"issue":"4","key":"6976_CR32","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1155\/2013\/539524","volume":"27","author":"IS Soon","year":"2013","unstructured":"Soon IS, deBruyn JCC, Wrobel I. Immunization history of children with inflammatory bowel disease. Can J Gastroenterol. 2013;27(4):213\u20136.","journal-title":"Can J Gastroenterol"},{"key":"6976_CR33","unstructured":"Australian Government. Invasive meningococcal disease national surveillance report. Department of Health website. https:\/\/www.health.gov.au\/internet\/main\/publishing.nsf\/Content\/5FEABC4B495BDEC1CA25807D001327FA\/$File\/19-July-2017-IMD-Surveillance-report.pdf. Updated July 19,\u00a02017. Accessed 22\u00a0Mar\u00a02018."},{"key":"6976_CR34","unstructured":"Melbourne Vaccination Education Centre. Meningococcal vaccines in special risk (immunosuppressed) adolescents. Melbourne Vaccination Education Centre website. http:\/\/www.mvec.vic.edu.au\/immunisation-references\/meningococcal-vaccines-in-special-risk-immunosuppressed-adolescents\/. Updated April 2017. Accessed 22\u00a0Mar\u00a02018."}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-021-06976-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-021-06976-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-021-06976-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,4]],"date-time":"2022-01-04T05:12:43Z","timestamp":1641273163000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-021-06976-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,4]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["6976"],"URL":"https:\/\/doi.org\/10.1186\/s12879-021-06976-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-116911\/v1","asserted-by":"object"}]},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,4]]},"assertion":[{"value":"27 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approval was obtained from the Royal Children\u2019s Hospital Human Research Ethics Committee, who provided a consent waiver as this was a retrospective study.  All methods were performed in accordance the Declarations of Helsinki. RCH Human Research Ethics Committee HREC#35060A.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Cmpeting interests"}}],"article-number":"6"}}